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Abstract Although a few promoters that direct intestinal
epithelial cell-specific expression in transgenic animals have
been reported, they are not necessarily appropriate for transgenic
studies in terms of activity and tissue specificity. Here, we
examined the tissue specificity of transgene expression directed
by the 2.8-kb promoter region of the T3b gene, which encodes one
of the non-classical major histocompatibility complex class I
molecules. The transgene was expressed exclusively in the
epithelial cells of the small and large intestines at high levels.
The results indicate that the T3b promoter is useful for directing
transgene expression specifically in intestinal epithelial cells.
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1. Introduction
In£ammatory bowel disease (IBD), i.e. Crohn’s disease or
ulcerative colitis, is an idiopathic chronic disease. Although
many studies have shown abnormalities of the mucosal im-
mune responses in IBD, its precise pathogenesis has not been
elucidated. Recently, various animal models of chronic intes-
tinal in£ammation have been reported [1], such as interleukin
(IL)-2 [2], IL-10 [3], and KL TCR knockout mice [4], or gp39
(CD40 ligand) [5], and IL-7 transgenic mice [6]. Experimental
colitis models, such as TNBS (2,4,6-trinitrobenzensulfonic
acid)-induced colitis, have also been reported [7]. Studies of
human IBD have implicated cytokines in the disease process,
consistent with results from animal models [8^10]. To further
investigate the roles of various cytokines in the in£ammatory
tissues, it would be useful to express in the intestinal epithe-
lium various transgenes that might modulate the local im-
mune reaction and to examine their e¡ects on the develop-
ment of IBD. Transcriptional promoters that can direct
transgene expression speci¢c to large intestinal epithelial cells
are needed for such experiments. However, only a few pro-
moters have been reported.
The T3b gene encodes one of the thymic leukemic antigens,
which are non-classical major histocompatibility complex
(MHC) class I molecules, in the C57BL/6 mouse strain [11^
13]. It has been shown to express strongly in the epithelial
cells of the intestine of normal C57BL/6 mice. In the present
study, we examined the tissue speci¢city of transgene expres-
sion driven by a 2.8-kb sequence that includes the promoter
and upstream non-coding region of the mouse T3b gene. The
expression of the transgene was examined by Northern blot
analysis, RT-PCR, and immunohistochemistry. The results
show that this 2.8-kb promoter region is su⁄cient to drive
high levels of transgene expression that is restricted to the
epithelial cells of the small and large intestines. Thus, this
promoter region includes the cis-acting elements necessary to
recapitulate the tissue-speci¢c expression pattern of the endog-
enous T3b gene.
IL-12 is a heterodimeric cytokine composed of two disul-
¢de-linked subunits, p40 and p35. It is produced by macro-
phages and antigen-presenting cells [14]. The p35 subunit of
IL-12 is expressed in many cell types, whereas the p40 subunit
(IL-12 p40) is inducible, can bind to the IL-12 receptor (and
does so especially well in a homodimeric form), and blocks
IL-12 from binding to the receptor. IL-12 p40 is considered to
be a natural regulator of IL-12 activity [15,16]. Recent reports
have shown that IL-12 is a key cytokine for Th1 cell develop-
ment in organ-speci¢c autoimmune diseases [17]. In Crohn’s
disease, IL-12 production in the in£ammatory site has been
studied [18,19]. However, the precise role of IL-12 in IBD has
not been clari¢ed. To study this issue, transgenic mice over-
expressing IL-12 p40 in the intestinal epithelial cells would be
very useful. The present study demonstrates that the T3b pro-
moter can be used to control transgene expression in the small
and large intestinal mucosa for such purposes.
2. Materials and methods
2.1. DNA construct
The SAP-IL-12 p40 plasmid contained the human SAP (serum
amyloid P component) promoter, the IL-12 p40 cDNA with 17 bp
of upstream and 10 bp of downstream non-coding sequences in addi-
tion to the approximately 1-kb complete IL-12 p40 coding sequence,
and rabbit L-globin gene sequences from the second exon to the poly-
adenylation signal [20]. The T3b-IL-12 p40 transgene was constructed
by replacing the SAP promoter of the SAP-IL-12 p40 plasmid with
the 2.8-kb SphI-HindIII T3b promoter region obtained from the T3b
gene cloned into the pUC18 plasmid [11]. Finally, a 6.0-kb SphI-XhoI
T3b-IL-12 p40 DNA fragment was puri¢ed and used for microinjec-
tion.
2.2. Generation of T3b-IL-12 p40 transgenic mice
BDF1, C57BL/6J, and MCH-ICR mice purchased from CLEA Ja-
pan Inc. (Tokyo, Japan) were used throughout this study. Mice were
maintained under speci¢c pathogen-free conditions in the animal fa-
cility at Osaka University Medical School. The transgene was micro-
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injected into the pronuclei of BDF1 fertilized eggs as described. For
screening founder mice, tail DNA was isolated by the SDS-proteinase
K method. Founders were genotyped by PCR using speci¢c primers
for the transgene. The following oligonucleotides were used as a for-
ward primer, 5P-GCTGGTTATTGTGCTGCTTC-3P and a backward
primer, 5P-GGTTCACTGTTTCTCCAGGG-3P. The PCR conditions
were 95‡C for 1 min, 60‡C for 2 min, 72‡C for 2 min, and 28 cycles at
94‡C for 1 min, 58‡C for 1 min, 72‡C for 1 min followed by an
extension for 10 min at 72‡C.
2.3. Southern and Northern blot analysis
Mouse tail DNA was isolated and quanti¢ed using a spectropho-
tometer. DNA (1.5 Wg) was digested with HindIII, fractionated by
electrophoresis on 0.8% agarose gels, and blotted onto Hybond N
membranes (Amersham Corp., Arlington Heights, IL, USA). The
IL-12 p40 cDNA was used as the probe. Probe binding was detected
by enhanced chemiluminescence using Gene Images (Amersham), ac-
cording to the supplier’s instruction.
Total RNA was isolated from homogenized tissue by the guanidi-
nium isothiocyanate/CsCl method. RNA was quanti¢ed using a spec-
trophotometer, and 10 Wg of total RNA was fractionated by electro-
phoresis on 0.9% agarose gels made with formaldehyde and blotted
onto Hybond N membranes. IL-12 p40 cDNA and human L-actin
gene DNA (Wako Pure Chemicals, Tokyo, Japan) were used as
probes. Probe detection was performed using the Gene Images system.
2.4. PCR detection of IL-12 p40 mRNA
RNA was reverse-transcribed with Superscript reverse transcriptase
(Gibco BRL, Rockville, MD, USA) and oligo dT at 42‡C for 2 h. The
reverse-transcribed samples were then subjected to PCR using Taq
polymerase. For IL-12 p40 and hypoxanthine phosphoribosyl
transferase (HPRT) mRNA detection, speci¢c oligonucleotide
primers were designed as follows: IL-12 p40 forward primer, 5P-
AGCTTGGATCCTGAGAACTTC-3P, IL-12 p40 backward primer,
5P-GGTTCACTGTTTCTCCAGGG-3P, HPRT forward primer, 5P-C-
TCGAAGTGTTGGATACAGG-3P, HPRT backward primer, 5P-TG-
GCCTATAGGCTCATAGTG-3P. These primers were designed to
encompass the intronic sequences, so that any PCR products ampli-
¢ed from genomic DNA contaminating the RNA preparation could
be distinguished. The PCR reaction conditions were 95‡C for 1 min,
60‡C for 2 min, 72‡C for 2 min, and 22^26 cycles at 94‡C for 1 min,
60‡C for 1 min, 72‡C for 2 min followed by an extension for 8 min at
72‡C. PCR products were separated by electrophoresis on 2% agarose
gels.
2.5. Immunohistochemistry
Samples were ¢xed in periodate^lysine^4% paraformaldehyde (4%
PLP) overnight at 4‡C and frozen in OCT compound (Tissue-TEK,
Miles, Elkhart, IN, USA). Serial sections (6 Wm thick) were cut with a
cryostat and placed on APS (3-amino-propyltriethoxysilane)-coated
slides. Blocking was performed in phosphate-bu¡ered saline (PBS,
pH 7.4) containing 1% bovine serum albumin (BSA) for 10 min at
room temperature. Samples were washed three times in PBS and then
incubated overnight at 4‡C with a rat anti-mouse IL-12 (p40/p70)
monoclonal antibody, C15.6 (PharMingen, San Diego, CA, USA),
at a concentration of 2.5 Wg/ml in PBS containing 1% BSA. The slides
were washed three times in PBS. Endogenous peroxidase was
quenched by incubating the samples in 0.3% H2O2/methanol for 10
min at room temperature. The slides were incubated overnight at 4‡C
with the secondary antibody, F(abP)2 fragments of anti-rat immuno-
globulin coupled to horseradish peroxidase (Amersham Pharmacia
Biotech, Bucks, UK). Following subsequent washes in PBS, the color
reaction was developed with diaminobenzidine. Slides were counter-
stained with hematoxylin.
3. Results
3.1. T3b-IL-12 p40 transgenic mice
Transgenic mice were generated using a transgene that con-
tained the 2.8-kb T3b promoter, the mouse IL-12 p40 cDNA,
and rabbit L-globin genomic sequences from the second exon
to the polyA signal (Fig. 1). Six founders carrying this trans-
gene were identi¢ed, and their phenotypes were apparently
normal. These transgenic mice were backcrossed with
C57BL/6 mice, and the transgene was transmitted to the
next generation in four founder lines: #9, #13, #20, and #24.
The copy number of the transgene in the mouse genome
was estimated by Southern blot analysis. As judged from the
hybridizing intensity of the bands corresponding to the trans-
gene, the four transgenic founder lines carried 5^10 copies of
the T3b-IL-12 p40 transgene (data not shown).
3.2. Transgene expression in T3b-IL-12 p40 transgenic mice
To examine whether the T3b-IL-12 p40 transgene was ex-
pressed in the intestine of the transgenic mice, Northern blot
analysis was performed using an IL-12 p40 cDNA probe (Fig.
2). Expression levels of IL-12 p40 mRNA in the large intestine
were compared (Fig. 2A). IL-12 p40 mRNA was highly ex-
pressed in all four lines, and was especially high in line #13,
but was not detectable in their non-transgenic littermates.
Expression of the T3b-IL-12 p40 transgene in other major
Fig. 1. The T3b-IL-12 p40 transgene construct. The T3b-IL-12 p40
transgene contained the T3b promoter, IL-12 p40 cDNA, and the
rabbit L-globin gene sequences from the second exon to the poly-
adenylation signal.
Fig. 2. Expression of IL-12 p40 mRNA in the T3b-IL-12 p40 trans-
genic mouse. Total RNAs (10 Wg per lane) obtained from tissues of
IL-12 p40 transgenic mice and non-transgenic littermates were sub-
jected to Northern blot analysis and probed with IL-12 p40 cDNA
or L-actin DNA. A: Expression of IL-12 p40 mRNA in the large
intestine of T3b-IL-12 p40 transgenic mice and non-transgenic litter-
mates from lines #9, #13, #20, and #24. B: Expression of IL-12
p40 mRNA in major organs of a line #20 transgenic mouse.
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organs was examined in detail using a transgenic mouse from
line #20. IL-12 p40 mRNA was detected in both the large and
small intestines of the transgenic mouse. Low levels of the
transgene transcript were also detected in the stomach, but
none was seen in any other organs, including the thymus
(Fig. 2B).
For a more detailed and sensitive analysis of the tissue
speci¢city of transgene expression, total RNA was isolated
from more organs and tissues of a line #20 transgenic mouse
and its non-transgenic littermate and subjected to RT-PCR
(Fig. 3). Transgenic IL-12 p40 mRNA was expressed exclu-
sively in the gastrointestinal tract, following this order: large
intestines small intestines stomach, consistent with the re-
sults from the Northern blot analysis. Analysis of a line #13
transgenic mouse by Northern blot and RT-PCR gave almost
identical results (data not shown).
Fig. 3. RT-PCR analysis of IL-12 p40 mRNA in the T3b-IL-12 p40 transgenic mouse. RNA was reverse-transcribed using Superscript reverse
transcriptase and an oligo dT primer. PCR was performed to detect IL-12 p40 mRNA (upper panel) and HPRT mRNA (lower panel) using
speci¢c primers. PCR products were separated by electrophoresis on 2% agarose gels. The lengths of the expected products were 224 bp for
IL-12 p40 and 350 bp for HPRT.
Fig. 4. Immunohistochemical analysis. Sections of organs taken from a transgenic mouse and its non-transgenic littermate (6 Wm thick) were in-
cubated with rat anti-mouse IL-12 monoclonal antibody, C15.6, and then incubated with F(abP)2 fragments of anti-rat immunoglobulin coupled
with horseradish peroxidase. Color reactions were developed by diaminobenzidine. Samples were counterstained with hematoxylin. A: Large in-
testine of the transgenic mouse. B: Large intestine of its non-transgenic littermate. C: Small intestine of the transgenic mouse. Magni¢cation:
U78. D: Large intestine of the transgenic mouse. Magni¢cation: U156.
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3.3. Detection of IL-12 p40 molecule in transgenic mice
To investigate the cellular localization of transgene expres-
sion, immunohistochemical analysis of several tissues derived
from a #20 transgenic mouse and its non-transgenic littermate
were conducted using a monoclonal antibody against IL-12,
C15.6 (Fig. 4). The epithelial cells of the large intestine in the
transgenic mouse were strongly stained by C15.6 (Fig. 4A).
The colonic epithelial cells consist of two types of cells, i.e.
absorptive cells and mucus-secreting goblet cells. Close exami-
nation of the sections revealed that transgene expression was
restricted to mature absorptive cells facing the lumen, and
that immature absorptive cells in the crypt and goblet cells
failed to express the transgene (Fig. 4D). No signi¢cant stain-
ing was observed in the epithelial cells of the non-transgenic
littermate (Fig. 4B). No staining of the large intestine of the
transgenic mouse was seen in controls using the secondary
antibody alone (not shown).
Villous epithelial cells of the small intestine in the transgenic
mouse were also stained by C15.6 (Fig. 4C). The staining
pattern was similar to that of the colonic epithelial cells and
signi¢cant staining was restricted to mature epithelial cells
facing the lumen. Epithelial cells of the stomach were not
stained above background (not shown).
4. Discussion
A number of tissue-speci¢c promoters have been used to
produce transgenic mice for various purposes; e.g. the pre-
proinsulin promoter [21], K-myosin heavy chain promoter
[22], and Clara cell 10-kDa protein (CC10) promoter [23]
have been shown to direct transgene expression restricted to
pancreatic L cells, heart muscle cells, and lung Clara cells,
respectively. Until now, a few promoters that direct intestinal
epithelial cell-speci¢c expression in transgenic animals have
been reported [24^28]. However, they are not necessarily ap-
propriate for transgenic studies on IBD in terms of activity
and tissue speci¢city; e.g. the fatty acid binding protein pro-
moter drives expression only in the small intestine, but not in
the large intestine [24^26]. Here we show that transgene ex-
pression under the T3b promoter was stronger in the epithe-
lium of the large intestine than in the small intestine in our
transgenic mice. The transgene expression under the T3b pro-
moter was largely restricted to the intestinal epithelium. Thus,
this promoter should provide a useful tool to study the mo-
lecular mechanisms of the pathogenesis of chronic in£amma-
tory enterocolitis and also colorectal cancers. Furthermore,
this promoter may be used to express genes exclusively in
intestinal epithelial cells when they are introduced via viral
vectors for therapeutic purposes.
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